ABSTRACT
BACKGROUND: We evaluated the effectiveness and cost-effectiveness of the Incredible Years® Teacher Classroom Management (TCM) programme as a universal intervention, given schools' important influence on child mental health. METHODS: A two-arm, pragmatic, parallel group, superiority, cluster randomised controlled trial recruited three cohorts of schools (clusters) between 2012 and 2014, randomising them to TCM (intervention) or Teaching As Usual (TAU-control). TCM was delivered to teachers in six whole-day sessions, spread over 6 months. Schools and teachers were not masked to allocation. The primary outcome was teacher-reported Strengths and Difficulties Questionnaire (SDQ) Total Difficulties score. Random effects linear regression and marginal logistic regression models using Generalised Estimating Equations were used to analyse the outcomes. TRIAL REGISTRATION: ISRCTN84130388. RESULTS: Eighty schools (2075 children) were enrolled; 40 (1037 children) to TCM and 40 (1038 children) to TAU. Outcome data were collected at 9, 18, and 30-months for 96, 89, and 85% of children, respectively. The intervention reduced the SDQ-Total Difficulties score at 9 months (mean (s.d.):5.5 (5.4) in TCM v. 6.2 (6.2) in TAU; adjusted mean difference = -1.0; 95% CI-1.9 to -0.1; p = 0.03) but this did not persist at 18 or 30 months. Cost-effectiveness analysis suggested that TCM may be cost-effective compared with TAU at 30-months, but this result was associated with uncertainty so no firm conclusions can be drawn. A priori subgroup analyses suggested TCM is more effective for children with poor mental health. CONCLUSIONS: TCM provided a small, short-term improvement to children's mental health particularly for children who are already struggling.
Subject(s)
Child Behavior , Educational Personnel , Schools , Students/psychology , Child , Child, Preschool , Cluster Analysis , Cost-Benefit Analysis , England , Female , Humans , Linear Models , Logistic Models , Male , Program Evaluation , Social BehaviorABSTRACT
OBJECTIVE: To evaluate the safety, tolerability, and clinical activity of a single intratympanic injection of OTO-104, sustained-release dexamethasone formulation, in patients with unilateral Ménière's disease. STUDY DESIGN: Prospective, double-blind, randomized, placebo-controlled, dose-escalation study of 16 weeks' (4-wk lead-in before dosing; 12-wk follow-up after dosing) duration for each patient. SETTING: Fifteen centers (physician offices and academic or tertiary referral centers). PATIENTS: Forty-four patients aged 22 to 75 years. INTERVENTION: Single intratympanic injection of OTO-104 (3 or 12 mg) or placebo. MAIN OUTCOME MEASURES: Safety and tolerability were assessed via adverse event reports, otoscopy, audiometry, and tympanometry. Clinical activity was assessed primarily as changes in vertigo frequency. RESULTS: OTO-104 was well tolerated, with no impact on hearing function. Plasma levels were observed in a few patients and were barely quantifiable. The most frequently reported adverse event considered related to investigational product was tympanic membrane perforation; no clinical sequelae were associated with these perforations and all were graded mild or moderate. At Month 3, the observed mean ± standard deviation (SD) change from baseline in vertigo frequency was -0.124 ± 0.153, -0.147 ± 0.166, and -0.211 ± 0.153 for the placebo, 3-mg OTO-104, and 12-mg OTO-104 groups, respectively; corresponding to 42%, 56% and 73% reductions in vertigo frequency, respectively. Similar results were observed for tinnitus, measured by the Tinnitus Handicap Inventory (THI-25). CONCLUSION: OTO-104 was safe and well tolerated. Although the sample size was small, the data suggest 12 mg of OTO-104 was associated with a clinically meaningful reduction in vertigo frequency compared to placebo 3 months after treatment.
Subject(s)
Dexamethasone/therapeutic use , Glucocorticoids/therapeutic use , Meniere Disease/drug therapy , Vertigo/drug therapy , Adult , Aged , Dexamethasone/administration & dosage , Dexamethasone/adverse effects , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Female , Glucocorticoids/administration & dosage , Glucocorticoids/adverse effects , Humans , Male , Middle Aged , Placebos , Treatment Outcome , Tympanic MembraneABSTRACT
OBJECTIVE: To evaluate the efficacy and safety of DM/Q (capsules containing dextromethorphan [DM] and quinidine [Q]) compared with placebo, taken twice daily, for the treatment of pseudobulbar affect over a 12-week period in multiple sclerosis patients. METHODS: A total of 150 patients were randomized in a double-blind, placebo-controlled study to assess pseudobulbar affect with the validated Center for Neurologic Study-Lability Scale. Each patient also recorded the number of episodes experienced between visits, estimated quality of life and quality of relationships on visual analog scales, and completed a pain rating scale. RESULTS: Patients receiving DM/Q had greater reductions in Center for Neurologic Study-Lability Scale scores than those receiving placebo (p < 0.0001) at all clinic visits (days 15, 29, 57, and 85). All secondary end points also favored DM/Q, including the number of crying or laughing episodes (p Subject(s)
Affect/drug effects
, Dextromethorphan/therapeutic use
, Excitatory Amino Acid Antagonists/therapeutic use
, Multiple Sclerosis/drug therapy
, Multiple Sclerosis/psychology
, Quinidine/therapeutic use
, Aged
, Crying
, Dextromethorphan/adverse effects
, Dextromethorphan/pharmacokinetics
, Double-Blind Method
, Drug Combinations
, Excitatory Amino Acid Antagonists/adverse effects
, Excitatory Amino Acid Antagonists/pharmacokinetics
, Female
, Humans
, Laughter
, Male
, Middle Aged
, Pain Measurement/drug effects
, Quality of Life
, Quinidine/adverse effects
, Quinidine/pharmacokinetics